NOTCH1 and B-cell chronic lymphocytic leukemia: Among anti-CD20 antibody therapies, obinutuzumab with higher efficacy compared to rituximab, has shown to overcome the refractoriness in CLL patients carrying NOTCH1 mutation [33].